Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2025)
Historic Cash from Operations for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$17.2 million.
- Arcturus Therapeutics Holdings' Cash from Operations rose 2782.78% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.3 million, marking a year-over-year increase of 293.55%. This contributed to the annual value of -$59.7 million for FY2024, which is 23011.22% down from last year.
- Arcturus Therapeutics Holdings' Cash from Operations amounted to -$17.2 million in Q3 2025, which was up 2782.78% from -$5.8 million recorded in Q2 2025.
- In the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations registered a high of $160.3 million during Q4 2022, and its lowest value of -$49.0 million during Q1 2022.
- In the last 5 years, Arcturus Therapeutics Holdings' Cash from Operations had a median value of -$30.1 million in 2024 and averaged -$12.6 million.
- Per our database at Business Quant, Arcturus Therapeutics Holdings' Cash from Operations crashed by 54078.71% in 2021 and then skyrocketed by 47710.66% in 2022.
- Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Cash from Operations stood at -$42.5 million in 2021, then surged by 477.11% to $160.3 million in 2022, then plummeted by 100.39% to -$629000.0 in 2023, then surged by 54.85% to -$284000.0 in 2024, then plummeted by 5939.08% to -$17.2 million in 2025.
- Its last three reported values are -$17.2 million in Q3 2025, -$5.8 million for Q2 2025, and -$35.1 million during Q1 2025.